Login to Your Account

Royalty Sale Repeat: Vertex Adds $152M to Back CF Work

By Jennifer Boggs
Managing Editor

Wednesday, November 20, 2013
Vertex Pharmaceuticals Inc. isn’t above using a good trick twice. Back in 2008, the Cambridge, Mass.-based firm picked up $160 million by selling royalty rights to two Glaxosmithkline plc-marketed drugs to help push through late-stage testing with then-game-changing hepatitis C virus (HCV) drug telaprevir. Fast forward five years, and Vertex again is opting for a royalty sale to pad its coffers.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription